Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRB-602
- Development stage
- Preclinical
- Lead developer
- Corbus Pharmaceuticals
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CRB-602 is a monoclonal antibody that specifically inhibits both integrins αvβ6 and αvβ8, which have been implicated in fibrotic diseases and cancers of epithelial origin. By targeting these integrins, CRB-602 is designed to block the activation of transforming growth factor β (TGFβ), a multifunctional cytokine that plays a key role in fibrosis and promotes cancer growth and metastasis via its effects in the tumor microenvironment. The dual inhibition of αvβ6 and αvβ8 is considered a rational approach to managing fibrotic diseases and carcinomas. CRB-602 was developed by Panorama Research and later licensed and developed by Corbus Pharmaceuticals for potential use in oncology and fibrotic disease indications[1][2][4][7][8][9][10][12].
- Brand names
- CRB-602CRB602CRB 602
- Other names
- CRB602CRB-602CRB 602
02
Targets
αVβ6 (Integrin αVβ6)αVβ8 (Integrin alpha V beta 8)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on CRB-602.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRB-602.